Amgen (NASDAQ: AMGN) today announced a $900 million expansion of its Ohio manufacturing facility, bringing the total number of jobs created to 750 and the total investment in Central Ohio to over $1.4 ...

Cantor Fitzgerald downgraded Amgen (AMGN) to Neutral from Overweight.Stay Ahead of the Market: Discover outperforming stocks and invest ...

As previously reported, Cantor Fitzgerald downgraded Amgen (AMGN) to Neutral from Overweight with a price target of $305, down from $340, as ...

It was backed initially by several million US dollars in venture capital funding and its first CEO, George Rathamann, was a former Vice President at Abbott. The Californian location put Amgen ...

Amgen is facing a slowdown in uptake of its first-to-market KRAS inhibitor Lumakras as a second-line therapy for KRAS-mutated non-small cell lung cancer (NSCLC), so is understandably excited by ...

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Many patent applicants currently face difficulty in obtaining antibody claims because of written description and enablement ...

Amgen’s stock dipped 1.3% to $273.68, but that’s still better than the broader market’s ugly faceplant. This underperformance adds to a 12.26% decline over the past month, outpacing losses in both the ...

Rossby Financial LCC recently grabbed 901 Amgen shares, throwing $235,000 into the biotech ring. Meanwhile, a parade of hedge funds also scooped up shares like bargain-hunters at a Wall Street yard ...